BioCentury
ARTICLE | Tools & Techniques

Isis fights antisense cynicism

October 11, 1993 7:00 AM UTC

Antisense technology has generated a great deal of skepticism among investors, who worry about everything from whether oligonucleotides get into cells, to manufacturing, to price.

Stanley Crooke, Isis Pharmaceuticals Inc. chairman, president and CEO, met with BioCentury recently to outline the progress against the critics' concerns. His comments were echoed by a new report from the analyst firm of Mehta and Isaly, which supports Crooke's contention that antisense is maturing more rapidly than even some experts are aware. ...